Cellarity’s Post

⚕ Today, Curia held its briefing webinar on our Life Sciences Industrial Strategy implementation report for a New Government, bringing together six months of work. Covering themes from governance and implementation, to clinical uptake, adoption and improved population outcomes, we were pleased to be joined by Curia's Health, Care, and Life Sciences Research Group Advisors Dr Keith Ridge CBE Prof. Ann Lloyd Keen and Corinna Bull as well as panellists including: - Michael Lewis (NIHR), - Jim McArdle (IQVIA UK and Ireland ) - Peter Donnelly (Genomics plc) - Helen Dent (British In Vitro Diagnostics Association (BIVDA)) - Chris Lowe (Revvity). The report will be made available to Curia's Health, Care, and Life Sciences Research Group Subscribers, as well as to public sector and third sector professionals. To find out more about becoming a subscriber, email team@curiauk.com. To buy a copy of the report, please find more details here: https://lnkd.in/gmudCkSQ #Health #Care #LifeSciences #NHS #Innovation #Research #Clinical #Clinician #Healthcare #UKPolitics #UKGovernment #ICB #Genomics #HealthTech #MedTech #Medicines #HealthInnovation #Policy #PublicPolicy

💡The future is bright. There is a lot we can do to develop better treatments for people who suffer from disease. 👉Want to know more about our innovation programs? 🩺From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), 🌟Discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. 🙌“It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Read more about the 7 ways Teva is collaborating to innovate ▶️ https://lnkd.in/duHfVYru #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships #RnD

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/ew669QYC #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/gYh2wUfN #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/dJ9P9Jx2 #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/dWh9chg7 #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/grfK39Mu #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/dDPHH5aU #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/dRzfRMjE #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/dzq_qgGw #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships